HEALEY ALS Platform Trial

Weekly Q&A – June 23, 2022



MGH	MASSACHUSETTS
1811	GENERAL HOSPITAL
MGH 1811	GENERAL HOSPITAL



Sean M. Healey & AMG Center for ALS at Mass General








































The Arthur M. Blank FAMILY FOUNDATION






Guest Speaker

Jackie Whitesell, MD Platform Trial Site Investigator Saint Alphonsus Regional Medical Center, Boise ID



SAINT ALPHONSUS NEUROLOGY ALS CLINIC



ABOUT US

Mulvaney

Our clinic serves patients in Idaho, Oregon, and Nevada. We serve a rural population. We have 7 neurologist plus 2 neuro-hospitalists. We have a monthly multidisciplinary ALS team We have a dedicated neurology research coordinator.



NEUROLOGY CLINIC TRIALS

ALS

Healey Platform trial

MS MS registry COREVITAS



OUR TEAM



PHYSICAL THERAPIST (LIZ ARMSTRONG) RESPIRATORY THERAPY (JAMIE GRANDSTAFF) SPEECH THERAPY (SUZANNE NEIDERMEYER) MEDICAL ASSISTANT (TRISHIA STREET) RESEARCH COORDINATOR (JOSHUA HARRISON) MEDICAL EQUIPMENT/LOAN CLOSET (SHANE DAVIS AND MIKE MCHARGUE)

ALSA CARE SERVICE COORDINATOR (HEIDI FRANTZ)

FUTURE DIRECTIONS/GOALS



We are applying for grant funding to help with patient travel expenses to clinical trial sites

OUTREACH CLINIC


I have taken a part-time position at VA Boise and see ALS there

DIETICIAN AND SOCIAL WORK

We are working to fill both needs



The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Enrollment Updates (as of June 23, 2022)

• 82 individuals have signed informed consent

• 50 individuals have been randomized within Regimen E

Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

New Resource

 Printer-friendly "Evergreen" Platform Trial General Info Brochure is available online!

The HEALEY ALS Platform Trial was designed to decrease the amount of time it will take to find successful therapies, improve active study medication to placebo ratio, and increase access for participants. One of the innovative features of the Platform Trial is that enrollment will continue perpetually as more investigational medications are added over time.



Am I Eligible?

What to Expect in the Trial Process Download Trial Brochure

https://bit.ly/3QJSLem



HEALEY ALS Platform Trial

A nationwide network of research centers in the Northeast ALS (NEALS) Consortium are partnering with the Sean M. Healey & AMG Center to conduct this first-of-its-kind platform trial for people living with ALS. The mission is to find answers as quickly as possible by testing multiple drugs using a shared platform.



https://bit.lv/31EKT

Healey Center Sean M. Healey & AMG Center for ALS at Mass General

Trial Highlights:

Multicenter Trial

More than 70 sites across the US are participating in the Platform Trial, working together to enroll 160 participants for each regimen.

3:1 Active Drug to Placebo Ratio

Participants have a 75% chance of receiving active study drug, and a 25% chance of receiving placebo.

Open Label Extension (OLE)

Upon completion of the 24-week trial, participants may have the option to enroll in the OLE for their regimen. During OLE, participants know with 100% certainty that they are receiving active study drug.

View map and contact info for participating research centers: <u>https://bit.ly/3IICv9t</u>

For general questions about the HEALEY ALS Platform Trial, Contact the Patient Navigator

healeyalsplatform@mgh.harvard.edu

833-425-8257 (HALT ALS)

Frequently Asked Questions

What is a platform trial? The platform trial tests multiple investigational products in different participants using a common master protocol. New investigational products can be added to the platform; this means more opportunities to find groundbreaking therapies in a faster timeframe.

Why use a platform trial approach?

Platform trials are designed to decrease the time it takes to find effective therapies, reduce the number of participants on placebo, and increase access to research by conducting the same trial at multiple locations. The platform trial will remain open until safe and effective treatments are found for all people living with ALS.

What phase is this research trial?

The Platform Trial is a late-stage trial (Phase 2/3), so data derived from the trial, if positive, could be used to support the approval of new medication.


Stay Connected to the Platform Trial

Investigational products will be added to the HEALEY ALS Platform Trial through support by pharma, foundation partners, philanthropy, federal, and other fundraising initiatives.

that regimen

of OLE may vary.

Learn more about what to expect in the trial process: Sign up for the ALS Link to receive research news and updates via email:







https://bit.lv/3ExRal8

https://bit.ly/3xC6RXK https://bit.ly/3DvkJTa

il: Weekly Q&A

How are investigational products

The investigational products are selected by

a team of experts after careful review of the

pharmaceutical company and the science

of success for all forms of ALS based on

behind the study drug. Each investigational

product is believed to have an equal chance

What is meant by the term 'regimen'?

A regimen is designed to test the safety and

product. Participants in the trial are randomly

randomized to active drug or placebo within

Open Label Extension (OLE) allows participants

to receive the active drug for the regimen to

which they were assigned after completing the

24-week placebo-controlled trial. The duration

efficacy of one specific investigational

assigned to one regimen, and then

What is open label extension?

chosen for this trial?

available scientific evidence.



Boosting Awareness

- On 5/23/22, a research notification about the Platform Trial was sent out to 11,440 registrants on the CDC's National ALS Registry
- To view the CDC website or sign up for the National ALS Registry Newsletter:



https://bit.ly/2DObSSU



Dear ALS Registry Participant,

The <u>HEALEY ALS Platform Trial</u> is enrolling people living with Amyotrophic Lateral Sclerosis (ALS) to test the efficacy of multiple investigational products. The platform trial is designed to decrease the time it takes to test new potential therapies and increase access to research for people living with ALS. One of the innovative features of the Platform Trial is that enrollment will continue as more investigational products are added.

We partner with more than 50 research centers across the USA (view <u>site map</u>). If you would like to enroll in this trial, please contact the research team at any local participating center (HEALEY ALS Platform Trial sites <u>contact information</u>). Please note that the Platform Trial involves about 6 to 8 in-person study visits over the course of 6 months, so we encourage participants to pursue enrollment at conveniently located centers.

If you have questions about the HEALEY ALS Platform Trial or would like assistance connecting with a local site, please contact the Patient Navigator <u>via email</u> or phone 833-425-8257 (HALT ALS).

Additionally, our weekly Q&A <u>Webinars</u>, held on Thursdays at 5pm ET, are a great way to stay up to date about the Platform Trial and submit questions in real time.

For more information about the Platform Trial:

- Register to attend upcoming webinars or view recordings of previous webinars:
- Webinars
- Overview of the Platform Trial:
- General Information: Platform Trial
- <u>Something New is Here: HEALEY Platform Trial</u>
- <u>Frequently Asked Questions</u>
- What to Expect in the Trial Process
- Investigational Products in the Platform Trial:
 <u>Study Drugs</u>
- Find out if you or a loved one may be eligible to participate:
 Online Eligibility Checking Tool

Thank you,

The HEALEY ALS Platform Trial Patient Navigation Team

Please note: The National ALS Registry and ATSDR are not part of this project and have no control over it. Please directly contact the research staff listed in the attachment to this email.

If you want us to stop sending these notices, you can update the preferences on your registry account on the <u>National ALS Registry</u> website (<u>www.cdc.gpw/als</u>) by logging into your account and clicking on the "Update Account" link. Then uncheck the "I Agree" box under ALS Research Notification Consent form.

Patient Navigation Central resource for people living with ALS

E-mail:healeyalsplatform@mgh.harvard.edu



Weekly webinar registration:

Catherine Small





Phone: 833-425-8257 (HALT ALS)

https://bit.ly/3r6Nd2L

ALS Link sign-up:



https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:

June 30th- Gale Kittle, RN, MPH (Director, Outcomes Measurement Training) July 14th- Eufrosina Young, MD (Investigator at SUNY Upstate, New York)

Allison Bulat



The ALS Association/Northeast ALS Consortium Educational Webinar

Healey ALS Platform Trial Regimen E: A Participant's Guide

Friday, June 17, 2022 5:00 - 6:00 PM EDT

The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen E of the Healey ALS Platform Trial. The presenters will review some of the unique aspects of the regimen related to the intravenous administration. **Recording Available:**



https://bit.ly/39Hs3SI